Applications

1357 – F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

The proposed service is 18F-FDG PET scanning for the evaluation of breast cancer in patients who have locally advanced disease where other imaging does not provide sufficient information to determine appropriate treatment and in breast cancer patients where recurrent or metastatic disease is suspected and for whom active therapy is likely to be pursued.

Type: Investigative

Medical condition this application addresses

Breast cancer is the most common cancer in women. In determining the best treatment for each patient, it is important to know when there is locally advanced disease, suspected recurrent breast cancer or metastatic spread. Current diagnostic methods are inferior to PET in evaluation of locally advanced disease, recurrence of disease and identification of metastatic spread. PET provides superior information to guide appropriate medical management.

Meetings to consider this application

  • PASC meeting: 
    • 12 to 13 December 2013
    • 14 to 15 August 2014
  • ESC meeting: 8 to 10 October 2014
  • MSAC meeting: 26 to 28 November 2014